在LE-IUI周期中,对于排卵功能障碍和不明原因的不孕症的不同最佳卵泡大小:回顾性分析
Yihua Liang1,2, Haiyan Lin1,2, Qi Qiu1,2
1Reproductive Medicine Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
European journal of medical research
|March 3, 2025
概括
对于莱特醇子宫内授精 (LE-IUI) 周期的最佳主导性卵泡大小在排卵功能障碍和不明原因的不孕不育之间有所不同. 在≥19.0毫米的触发是最好的排卵功能障碍,而≤21毫米可能会改善无法解释的不孕不育的结果.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 不孕症治疗 不孕症治疗
- 辅助生殖技术 辅助生殖技术
背景情况:
- 排卵功能障碍和不明原因的不孕不育是不孕不育的常见原因.
- 以莱特醇为媒介的子宫内授精 (LE-IUI) 是广泛用于治疗这些疾病的方法.
- 确定激发排卵的最佳主导卵泡大小对于LE-IUI的成功至关重要.
研究的目的:
- 在患有排卵功能障碍的患者中,在LE-IUI周期的触发日确定最佳的主导卵泡大小.
- 为了确定患有不明原因不育症的患者在LE-IUI周期的触发日的最佳主导卵泡大小.
- 为了比较不同主导卵泡大小在LE-IUI周期中对妊娠结果的疗效.
主要方法:
- 对于排卵功能障碍的411个LE-IUI周期和411个无法解释的不孕不育的411个周期的回顾性分析.
- 使用倾向性得分匹配来确保可比的组.
- 根据触发日的主导毛囊大小分析了结果,包括HCG阳性,临床怀孕和活产率.
主要成果:
- 排卵功能障碍组的HCG阳性,临床怀孕和活产率明显高于无法解释的不孕症组.
- 在排卵功能障碍中,19-21.0毫米和>21.0毫米的主导卵泡产生了比17-18.9毫米更好的结果.
- 在无法解释的不孕症中,毛囊>21.0毫米与较小的毛囊大小相比,较低的HCG阳性率有关.
结论:
- 对于接受LE-IUI的排卵功能障碍患者来说,在主导毛囊大小≥19.0毫米时触发排卵似乎是最佳的.
- 占主导的毛囊大小≤21毫米可能更有利于改善HCG阳性率在不明原因不育LE-IUI周期.
- 在确定LE-IUI周期中排卵诱导的最佳主导卵泡大小时,应考虑不孕症诊断.
更多相关视频
05:31OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
Published on: May 9, 2021
3.9K
05:32Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
Published on: August 11, 2023
1.6K
相关概念视频
Ovarian Cycle
907
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
907
In Vitro Fertilization
185
In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
185
Infertility in Females
255
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
255
Meiosis II
181.9K
Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...
181.9K
